USA: 
Europe: 
Email: 
Consultation
| Catalog: | C-FC-3230A |
| Product Type: | FCM Antibody |
| Size: | 50 µL/100 µL/200 µL |
| Reactivity: | Human |
| Specificity: | Human Cytokeratin 19/KRT19 |
| Analysis mode: | WB,FCM,IP |
| Host: | Mouse |
| Clonality: | Monoclonal |
| Isotype: | IgG3 |
| Alternate names: | keratin 19, type I |
| Form: | Liquid |
| Shipping: | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage: | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. |
| Purification method: | Protein A |
| Conjugation: | Unconjugated |
| Immunogen: | A synthetic peptide corresponding to the N-terminus of the human KRT19 |
| Buffer: | 0.2 μm filtered solution in PBS |
Cytokeratin 19 (KRT19) is a cytoplasmic intermediate filament protein, which is responsible for structural rigidity and multipurpose scaffolds. In several cancers, KRT19 is overexpressed and may play a crucial role in tumorigenic transformation. The KRT19 gene encodes cytokeratin 19, an element of the cytoskeleton whose expression is frequently altered in renal cell carcinoma (RCC).KRT19 was identified as one of the key biomarkers for distinguishing cholangiocarcinoma (CCA) and hepatocellular carcinoma. Expression of KRT19 was specifically high in breast cancers and significantly correlated with their invasiveness. Moreover, knockdown of KRT19 led to increased proliferation, migration, invasion, drug resistance, and sphere formation in breast cancer cells via an upregulated NOTCH signaling pathway.
Core Diagnostic Capabilities
Follow Us -
Copyright © 2025 Creative Biogene. All rights reserved.
